InMed Pharmaceuticals Inc. (INM): Nasdaq/NYSE listing notice — InMed receives Nasdaq notice of bid price deficiency; 180 days to cure

InMed Pharmaceuticals Inc.

Received Nasdaq notice on March 27, 2026; closing bid price below $1.00 for 30 consecutive days (Feb 11–Mar 26).
Must achieve $1.00 or more for 10 consecutive business days within 180 calendar days to regain compliance.
If not cured, may qualify for additional 180-day period, subject to other listing standards and possible reverse split.
No immediate effect on listing; shares continue trading on Nasdaq under symbol INM.
Company monitoring share price and exploring options, including reverse stock split if needed.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

InMed Pharmaceuticals Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 27, 2026, InMed Pharmaceuticals Inc. (the "Company") received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying it that the closing bid price of the Company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) during the February 11, 2026 to March 26, 2026 period. In accordance with applicable Nasdaq procedures, the Company has a period of 180 calendar days following the receipt of t

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001062993-26-001697

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.